PURPOSE:
To compare the 2-year visual and refractive outcomes with the Eyecryl Phakic Toric IOL (EP TIOL) (Biotech Vision Care Pvt Ltd) and Visian Toric ICL (TICL) (STAAR Surgical) for correction of high myopic astigmatism.
METHODS:
This prospective, interventional, non-randomized comparison study included eligible patients who underwent toric phakic IOL surgery in one or both eyes with either the EP TIOL or TICL for myopic astigmatism. Two years postoperatively, both lenses were compared for their safety, efficacy, stability, and patient satisfaction. Vector analysis of astigmatism was performed using the Alpins method with the ASSORT software (ASSORT Party Ltd).
RESULTS:
A total of 50 eyes were included, of which 25 eyes received EP TIOL implantation and the remaining 25 received TICL implantation. Preoperative mean ± standard deviation of spherical equivalent (SE) and cylinder was −10.15 ± 4.04 and −2.08 ± 0.86 diopters (D) in the EP TIOL group and −10.21 ± 3.97 and −2.17 ± 0.95 D in the TICL group, respectively. At 2 years of follow-up, there was no significant difference between the mean uncorrected distance visual acuity, corrected distance visual acuity, spherical equivalent, and residual astigmatism between the two groups (
P
> .05 for all parameters). Ninety-two percent of eyes in the EP TIOL group and 88% of eyes in the TICL group were within ±0.50 D of refractive astigmatism. Vector analysis of astigmatism showed a comparable Correction Index of 0.98 in the EP TIOL group and 0.94 in the TICL group, signifying a mild undercorrection of 2% and 6%, respectively. Two eyes in the TICL group underwent exchange for high vault and one eye required realignment due to significant postoperative rotation.
CONCLUSIONS:
At least for the first 2 years postoperatively, both toric phakic IOLs were safe and effective in managing high myopic astigmatism with comparable visual results and patient satisfaction.
[
J Refract Surg
. 2021;37(1):7–15.]
PURPOSE:
To report 1-year visual and refractive outcomes following PRESBYOND Laser Blended Vision using non-linear aspheric micro-monovision with the MEL 90 platform (Carl Zeiss Meditec GmbH).
METHODS:
Data were collected retrospectively for all patients who underwent treatment for simultaneous correction of refractive error and presbyopia from June 2015 to June 2018. Only those patients who completed at least 6 months of follow-up were included in the study.
RESULTS:
A total of 101 patients with a mean age of 51.05 ± 5.15 years (range: 40 to 65 years), of whom 38 patients had myopic and 63 patients had hyperopic refractive error with or without astigmatism, were included in the study. Mean preoperative spherical equivalent was −3.36 ± 1.86 diopters (D) in the myopia group and +1.75 ± 0.99 D in the hyperopia group. At 1 year, the mean spherical equivalent refraction was +0.13 ± 0.32 D in the distance eye and −1.42 ± 0.33 D (range: −0.88 to −2.50 D) in the near eye in the myopia group and −0.13 ± 0.24 D in the distance eye and −1.28 ± 0.31 D (range: −0.63 to −2.00 D) in the near eye in the hyperopia group. Two eyes in the hyperopia group underwent early enhancement for the near eye at 3 months. Ninety-seven percent of the patients in the myopia group and 96% in the hyperopia group were satisfied with their distance vision. Near vision satisfaction score was 95% for the myopia group and 89% for the hyperopia group.
CONCLUSIONS:
At 1 year, the aspheric micro-monovision protocol resulted in satisfactory and fairly stable visual outcomes in both myopic and hyperopic individuals.
[
J Refract Surg
. 2020;36(5):300–307.]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.